Douglas Lionel Powell

US Patent:

8389999, Mar 5, 2013

Filed:

Sep 28, 2010

Appl. No.:

12/892370

Inventors:

Anthony Buonassisi - Cambridge MA, US
Mariana Bertoni - Somerville MA, US
Ali Argon - Belmont MA, US
Sergio Castellanos - Sonora, MX
Alexandria Fecych - Somerville MA, US
Douglas Powell - Highland Heights OH, US
Michelle Vogl - Dekalb IL, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

H01L 29/04

US Classification:

257 75, 257 52, 257 59, 257 72, 438 57, 438 58, 438 97

Abstract:

A crystalline material structure with reduced dislocation density and method of producing same is provided. The crystalline material structure is annealed at temperatures above the brittle-to-ductile transition temperature of the crystalline material structure. One or more stress elements are formed on the crystalline material structure so as to annihilate dislocations or to move them into less harmful locations.

US Patent:

20030216288, Nov 20, 2003

Filed:

Feb 13, 2003

Appl. No.:

10/366288

Inventors:

Douglas Powell - Littleton MA, US
Nadine Weich - Brookline MA, US

Assignee:

Millennium Pharmaceuticals, Inc.

International Classification:

A61K031/00
A61K038/16
A61K048/00
A61K039/395
C12Q001/70

US Classification:

514/002000, 514/044000, 514/001000, 424/143100, 435/005000

Abstract:

The present invention relates to methods for the diagnosis and treatment of AIDS or an HIV-related disorder or disorders. Specifically, the present invention identifies the differential expression of 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 and 2045 genes in tissues relating to AIDS or an HIV-related disorder, relative to their expression in normal, or non-AIDS or HIV-related disease states, and/or in response to manipulations relevant to AIDS or an HIV-related disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various HIV-related disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating AIDS or an HIV-related disorder or disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of AIDS or an HIV-related disorder.

US Patent:

20040180332, Sep 16, 2004

Filed:

Feb 27, 2004

Appl. No.:

10/789241

Inventors:

Douglas Powell - Littleton MA, US

Assignee:

Millennium Pharmaceuticals, Inc.

International Classification:

C12Q001/70

US Classification:

435/005000

Abstract:

The present invention relates to methods for the diagnosis and treatment of AIDS or an HIV-related disorder or disorders. Specifically, the present invention identifies the differential expression of 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 and 46777 genes in tissues relating to AIDS or an HIV-related disorder, relative to their expression in normal, or non-AIDS or HIV-related disease states, and/or in response to manipulations relevant to AIDS or an HIV-related disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various HIV-related disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating AIDS or an HIV-related disorder or disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of AIDS or an HIV-related disorder.

US Patent:

20070031882, Feb 8, 2007

Filed:

Oct 11, 2006

Appl. No.:

11/545891

Inventors:

Douglas Powell - Littleton MA, US
Nadine Weich - Brookline MA, US

International Classification:

C12Q 1/68
C12P 21/06

US Classification:

435006000, 435069100

Abstract:

The present invention relates to methods for the diagnosis and treatment of AIDS or an HIV-related disorder or disorders. Specifically, the present invention identifies the differential expression of 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 and 2045 genes in tissues relating to AIDS or an HIV-related disorder, relative to their expression in normal, or non-AIDS or HIV-related disease states, and/or in response to manipulations relevant to AIDS or an HIV-related disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various HIV-related disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating AIDS or an HIV-related disorder or disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of AIDS or an HIV-related disorder.

US Patent:

20080095798, Apr 24, 2008

Filed:

Oct 18, 2006

Appl. No.:

11/582596

Inventors:

Robert Humphreys - Acton MA, US
Douglas Macmillan Powell - Littleton MA, US
John Zinckgraf - Sturbridge MA, US

International Classification:

A61K 48/00
A61K 39/12
A61K 39/02

US Classification:

4242041, 4242341, 514 44

Abstract:

Disclosed is a method for increasing vaccine potency whereby a subject's immune system is first primed with an Ii-Key hybrid peptide construct before the subject subsequently receives a vaccine for a pathogen of interest. The vaccine may be comprised of a protein or portion thereof that is encoded by the genome of the pathogen. The vaccine may also be a DNA vaccine comprised of DNA encoding a protein of the pathogen. The Ii-Key hybrid peptide construct includes the LRMK residues of Ii-Key protein and an MHC Class II epitope of the protein or portion thereof which is used in the vaccine. The Ii-Key construct may be administered in the form of a nucleic acid construct encoding the Ii-Key hybrid peptide. Priming with Ii-Key peptides enhances the immunogenicity of rHA protein and HA and HIV DNA vaccines. Methods are described relating to the use of Ii-Key hybrid constructs in vaccine protocols wherein the pathogen is HIV or Influenza A, including H5N1. Methods and compositions are described wherein the MHC Class II epitope of the Ii-Key hybrid is hemagglutinin encoded by Influenza A or the Gag protein encoded by HIV.

US Patent:

20100184093, Jul 22, 2010

Filed:

Aug 28, 2009

Appl. No.:

12/584048

Inventors:

Michael Donovan - Cambridge MA, US
Faisal Khan - Fishkill NY, US
Jason Alter - Stamford CT, US
Gerardo Fernandez - Yorktown Heights NY, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Douglas Powell - Bronxville NY, US
Valentina Bayer Zubek - Yonkers NY, US
Stefan Hamann - New Rochelle NY, US
Carlos Cordon-Cardo - New York NY, US
Jose Costa - Guilford CT, US

Assignee:

Aureon Laboratories, Inc. - Yonkers NY

International Classification:

G01N 33/53
C12M 1/34

US Classification:

435 721, 4352871

Abstract:

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.

US Patent:

20100310591, Dec 9, 2010

Filed:

Jan 28, 2010

Appl. No.:

12/695892

Inventors:

ROBERT HUMPHREYS - ACTON MA, US
DOUGLAS MACMILLAN POWELL - LITTLETON MA, US
JOHN ZINCKGRAF - STANDISH ME, US

International Classification:

A61K 39/145
C12N 5/02
C40B 30/06
C07K 14/00
C07K 7/06

US Classification:

4241861, 4242091, 435375, 506 10, 530324, 530328

Abstract:

The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii-key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components. In a particular embodiment, the hybrid peptides of the present invention comprise influenza MHC class II epitopes identified herein as being effective in generating an immune response and provide immunity to the individual.

US Patent:

20130080134, Mar 28, 2013

Filed:

Jun 4, 2012

Appl. No.:

13/488176

Inventors:

Michael Donovan - Newton MA, US
Faisal Khan - Fishkill NY, US
Jason Alter - Carlsbad CA, US
Gerardo Fernandez - San Jose CA, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Douglas Powell - Gettysburg PA, US
Valentina Bayer Zubek - Yonkers NY, US
Stefan Hamann - Cambridge MA, US
Jose Costa - Guilford CT, US

Assignee:

Fundação D. Anna Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Lisboa

International Classification:

G06F 19/00

US Classification:

703 11

Abstract:

In general, one aspect of the subject matter described in this specification can be embodied in methods for assessing risk associated with prostate cancer, the methods including the actions of receiving patient data, comparing, with a processor executing code, the patient data to one or more predictive models, the one or more predictive models comprising at least one of (a) a disease progression (DP) model, the DP model being configured to predicts a likelihood of developing significant disease progression, and (b) a favorable pathology (FP) model, the FP model being configured to predict a likelihood of having organ confined, low grade disease in a prostatectomy, and outputting one or more results of the comparison Other embodiments of the various aspects include corresponding systems, apparatus, and computer program products.